Germany Life Sciences Regulation in 2025: Navigating the EU Pharma Package, IVDR Compliance and Clinical Trial Reforms

Germany’s life sciences sector stands at a regulatory crossroads in 2025, shaped by sweeping EU-level reforms and evolving national implementation measures that together redefine how pharmaceutical companies, medical device manufacturers, and biotech firms operate within Europe’s largest healthcare market. The EU Pharmaceutical Package, the most ambitious overhaul of European medicines law in two decades, is advancing through legislative stages and promises to restructure everything from marketing authorisation timelines to regulatory data protection periods. Simultaneously, the delayed but now enforced In Vitro Diagnostic Regulation (IVDR) is compelling German diagnostics manufacturers to overhaul their compliance infrastructure, while the EU Clinical Trials Regulation (CTR) continues to reshape how studies are initiated and managed through the Clinical Trials Information System (CTIS).

For international companies and legal advisors operating in or entering the German market, understanding these intersecting regulatory currents is no longer optional, it is a strategic imperative.

The EU Pharmaceutical Package: What Germany’s Life Sciences Industry Must Prepare For

The European Commission’s proposed revision of the EU general pharmaceutical legislation, published in April 2023, represents the most comprehensive reform of the regulatory framework for human medicines since 2004. The package proposes replacing the existing Directive 2001/83/EC and Regulation (EC) No 726/2004 with a new single directive and a new single regulation, aiming to streamline authorisation processes, improve patient access to medicines, and address the growing challenge of antimicrobial resistance.

For Germany, home to roughly 500 pharmaceutical companies and one of Europe’s largest generics and biosimilar markets, the proposed changes carry profound commercial and operational implications. The European Parliament adopted its position on the package in April 2024, and trilogue negotiations between the Parliament, Council, and Commission are expected to determine the final legislative text during 2025 and into 2026.

Regulatory Data Protection: The Central Controversy

The most commercially significant provision in the draft legislation concerns the proposed reduction of regulatory data protection (RDP) for innovative medicines. Under the current framework, originator companies benefit from an 8+2+1 year data and market exclusivity structure. The Commission’s initial proposal suggested reducing the standard RDP period to six years, with possible extensions of up to two additional years where specific conditions are met, such as addressing an unmet medical need or conducting comparative clinical trials.

The European Parliament’s amendments proposed modifying these periods, and the Council’s general approach, reached in June 2024, introduced its own calibration. German industry associations, including the vfa (Association of Research-Based Pharmaceutical Companies) and BPI (German Pharmaceutical Industry Association), have voiced concern that shortened exclusivity windows could undermine Germany’s attractiveness as a location for pharmaceutical research investment, particularly when compared with incentive structures in the United States and China.

Industry observers expect the final text to land somewhere between six and eight years of standard data protection, with a tiered incentive system that rewards companies for launching across all 27 EU member states within a defined period. The likely practical effect will be to increase pressure on companies to develop pan-European launch strategies rather than focusing on a handful of high-revenue markets.

Centralised Procedure Reforms and EMA Timelines

The proposed legislation also seeks to accelerate the European Medicines Agency’s (EMA) assessment timelines. The Commission’s draft introduced a target of 180 days for the centralised marketing authorisation procedure, reduced from the current standard of 210 days, and proposed enhanced fast-track mechanisms for medicines addressing unmet medical needs and for crisis-relevant therapeutics.

Germany’s Federal Institute for Drugs and Medical Devices (BfArM), which serves as a major rapporteur and co-rapporteur for EMA assessments, will face operational changes as these accelerated timelines are implemented. Early indications suggest that German regulatory bodies are investing in digital assessment tools and workforce capacity to meet these compressed schedules, but the transition will require significant adjustment across the entire regulatory ecosystem.

Environmental Risk Assessment and Manufacturing Requirements

A notable addition to the revised framework is the reinforced emphasis on environmental risk assessment (ERA) for human medicines. The proposed legislation would make ERA results a factor in marketing authorisation decisions, a shift from the current approach where ERA findings are considered but cannot serve as grounds for refusing authorisation. For Germany’s chemical-pharmaceutical manufacturing base, which includes major production facilities along the Rhine corridor, this change introduces an additional compliance layer that intersects with Germany’s already stringent environmental regulations under the Federal Immission Control Act (BImSchG).

IVDR Compliance: Germany’s Diagnostics Sector Under Pressure

The EU In Vitro Diagnostic Regulation (EU) 2017/746, commonly referred to as IVDR, became fully applicable on 26 May 2022, replacing the former In Vitro Diagnostic Medical Devices Directive (98/79/EC). However, the transition has been anything but smooth. Recognising the industry-wide capacity constraints, the European Parliament and Council adopted Regulation (EU) 2023/607 in March 2023, which extended the transition periods for certain legacy IVDs to allow continued placing on the market under specific conditions through 2025, 2027, and 2028 depending on the device risk class.

Germany is the largest medical device and diagnostics market in Europe. German manufacturers produce a vast range of IVDs, from companion diagnostics and high-risk Class D products such as blood-grouping reagents and HIV tests, to lower-risk Class A self-test devices. The IVDR’s reclassification system significantly expanded the proportion of devices requiring Notified Body involvement, from approximately 8% under the former directive to an estimated 80% under the new regulation.

Notified Body Bottleneck

The most acute challenge facing German IVD manufacturers in 2025 relates to Notified Body capacity. As of early 2025, fewer than ten Notified Bodies have been designated under the IVDR across the entire EU. Germany’s TÜV SÜD and DEKRA are among the designated bodies, but demand for conformity assessments vastly outstrips available capacity. This bottleneck is particularly severe for Class C and Class D devices, which require the most intensive assessment procedures.

The German Federal Ministry of Health (BMG) and the German Institute for Medical Documentation and Information (DIMDI, now part of BfArM since 2020) have been engaged in supporting manufacturers through guidance documents and stakeholder workshops, but the structural supply-demand imbalance in Notified Body capacity remains the single largest compliance risk for the German diagnostics industry.

Practical Compliance Steps for German IVD Manufacturers

• Classification audit. Manufacturers must review every product against the IVDR’s Annex VIII classification rules. Many devices previously self-certified under the directive now require Notified Body certification under the regulation.
• Performance evaluation overhaul. The IVDR’s performance evaluation requirements (Articles 56–58) demand clinical evidence to a standard significantly higher than the former directive. German manufacturers should invest in structured literature reviews, performance studies, and post-market performance follow-up (PMPF) plans.
• UDI and EUDAMED registration. All IVDs must carry a Unique Device Identifier (UDI), and manufacturers are required to register devices and economic operators in the European Database on Medical Devices (EUDAMED). Although EUDAMED’s full functionality has been delayed, the UDI module and device registration module are operational, and compliance obligations are in force.
• Quality management system alignment. QMS must be aligned with the IVDR’s requirements, typically implemented through EN ISO 13485:2016 with IVDR-specific supplementary procedures. Notified Bodies will audit QMS compliance as part of the conformity assessment process.
• Legacy device strategy. For devices currently on the market under IVDD certificates, manufacturers must develop a clear transition roadmap, identifying which products can rely on extended transition periods and which require immediate IVDR certification applications.

Clinical Trial Reforms Under the EU Clinical Trials Regulation

The EU Clinical Trials Regulation (EU) No 536/2014 became applicable on 31 January 2022, replacing the former Clinical Trials Directive 2001/20/EC. The CTR introduced a harmonised EU-wide authorisation procedure managed through the Clinical Trials Information System (CTIS), a centralised portal and database operated by the EMA.

Germany remains one of the top countries for clinical trial activity in Europe. According to EMA data, Germany consistently ranks among the three most frequently selected member states for multinational clinical trials. Under the CTR, all new clinical trial applications submitted from 31 January 2023 onwards must be submitted exclusively through CTIS, and trials approved under the old directive were required to transition to the CTR framework by 30 January 2025.

Germany’s Role as Reporting Member State

Under the CTR’s assessment procedure, one EU member state acts as the Reporting Member State (RMS) for Part I of the assessment (covering the scientific and medicinal product aspects), while each concerned member state assesses Part II nationally (covering site-specific, ethical, and patient-related aspects). BfArM and the Paul-Ehrlich-Institut (PEI), the latter responsible for biologicals, vaccines, and advanced therapy medicinal products (ATMPs), serve as Germany’s competent authorities for clinical trial authorisation.

Germany’s ethics committee system, historically decentralised across the 16 federal states (Länder), has undergone adaptation to align with the CTR’s requirements. The responsible ethics committee now provides a coordinated opinion as part of the Part II assessment, and the federal-state coordination has been facilitated through the Arbeitskreis Medizinischer Ethik-Kommissionen, the working group of medical ethics committees in Germany.

Practical Implications for Sponsors

Sponsors running clinical trials in Germany under the CTR framework should be aware of several Germany-specific considerations that sit alongside the harmonised EU process:

• National fee structures. Clinical trial authorisation fees vary by member state. Germany’s fee schedule is set by the Kostenverordnung (cost regulation) associated with the German Medicinal Products Act (Arzneimittelgesetz, AMG), and sponsors should budget accordingly.
• Language requirements. While CTIS accepts documentation in English for Part I of the assessment, Part II documents, including patient-facing materials such as informed consent forms, patient information sheets, and labelling, must be provided in German.
• Insurance requirements. German law requires sponsors to hold clinical trial insurance (Probandenversicherung) in accordance with the AMG and the GCP Ordinance (GCP-Verordnung). This remains a national requirement that is unaffected by the CTR harmonisation.
• CTIS transition management. Sponsors with trials initially authorised under the old directive that continued beyond 30 January 2025 needed to ensure transition to the CTR. Failure to transition means the trial can no longer recruit new subjects in the EU.

Germany Life Sciences Regulation: The National Legislative Landscape

While EU regulations are directly applicable in Germany, several critical areas of life sciences regulation remain shaped by national legislation and administrative practice. Understanding the interplay between EU frameworks and German national law is essential for any company operating in this jurisdiction.

The Arzneimittelgesetz (AMG) and Its Evolving Role

Germany’s Medicinal Products Act (Arzneimittelgesetz, AMG) has long served as the central national statute governing pharmaceuticals. With the increasing shift toward directly applicable EU regulations, particularly the CTR and the anticipated new pharmaceutical legislation, the AMG’s role is evolving from primary regulatory instrument to implementing and supplementary statute. However, the AMG continues to govern several critical areas, including:

• National manufacturing and import licences. Pharmaceutical manufacturing and wholesale distribution authorisations in Germany are issued under the AMG by the competent Land (state) authority.
• Pharmacovigilance obligations. While the EU pharmacovigilance framework is harmonised, the AMG imposes specific national reporting obligations and designates BfArM and PEI as the national competent authorities for safety signal monitoring.
• Advertising and promotion. The Heilmittelwerbegesetz (HWG), Germany’s Medicinal Products Advertising Act, governs pharmaceutical advertising and is enforced alongside EU-level requirements. Germany maintains some of the strictest advertising restrictions in Europe, particularly regarding direct-to-consumer communication.

AMNOG and Health Technology Assessment

Germany’s Act on the Reform of the Market for Medicinal Products (Arzneimittelmarktneuordnungsgesetz, AMNOG), in force since 2011, established a mandatory early benefit assessment for new medicines entering the German market. Under AMNOG, the Federal Joint Committee (Gemeinsamer Bundesausschuss, G-BA) evaluates the additional therapeutic benefit of new active substances compared to an appropriate comparator therapy. The Institute for Quality and Efficiency in Health Care (Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen, IQWiG) conducts the assessment on behalf of G-BA.

The AMNOG framework is now intersecting with the EU Health Technology Assessment Regulation (EU) 2021/2282, which entered into force on 11 January 2022 and will apply from January 2025 for oncology products and ATMPs, with phased expansion to other therapeutic areas through 2030. Under this regulation, joint clinical assessments (JCAs) will be conducted at EU level, and the results will feed into national pricing and reimbursement processes. Germany’s G-BA will continue to make national benefit assessment decisions, but the clinical evidence base will increasingly be shaped at the European level.

Industry observers expect this dual-track system, EU joint clinical assessment feeding into Germany’s AMNOG procedure, to create both efficiencies and complexities. Companies will need to engage with the EU HTA process early while maintaining their current AMNOG dossier preparation capabilities.

Comparison: Key Regulatory Frameworks Affecting Germany’s Life Sciences Sector in 2025

Advanced Therapy Medicinal Products (ATMPs) in Germany

Germany has established itself as a leading hub for advanced therapy medicinal products, including gene therapies, somatic cell therapies, and tissue-engineered products. The Paul-Ehrlich-Institut (PEI) is the national competent authority for ATMPs and plays an active role in EMA’s Committee for Advanced Therapies (CAT).

The regulatory landscape for ATMPs in Germany is shaped by several converging factors in 2025. The EU Pharma Package includes provisions aimed at streamlining the regulatory pathway for ATMPs, including proposals for regulatory sandboxes and adaptive pathways. At the national level, Germany’s Hospital Reform Act (Krankenhausversorgungsverbesserungsgesetz, KHVVG), which passed in 2024, includes provisions intended to improve the integration of ATMPs into hospital-based care, addressing reimbursement barriers that have historically limited patient access.

The manufacturing of ATMPs, particularly autologous therapies that require patient-specific production, presents unique regulatory challenges under Germany’s GMP framework. PEI has issued specific guidance on ATMP manufacturing, and the German Pharmaceutical Inspection Co-operation Scheme (PIC/S) participates in international harmonisation efforts to ensure GMP standards keep pace with rapidly evolving manufacturing technologies such as automated cell processing and decentralised manufacturing models.

Data Protection and Digital Health: Intersections with Life Sciences Regulation

Germany’s life sciences sector increasingly operates at the intersection of pharmaceutical regulation and data protection law. The EU General Data Protection Regulation (GDPR), supplemented by Germany’s Federal Data Protection Act (Bundesdatenschutzgesetz, BDSG), governs the processing of personal data, including health data, in clinical trials, pharmacovigilance, real-world evidence studies, and digital health applications.

Two developments are particularly relevant for life sciences companies operating in Germany in 2025:

The European Health Data Space (EHDS)

The European Health Data Space Regulation, which reached political agreement in 2024, will create a framework for the secondary use of health data across EU member states. For the life sciences industry, this promises structured access to real-world health data for research, innovation, and regulatory purposes. Germany’s existing health data infrastructure, including data from statutory health insurance funds (gesetzliche Krankenversicherungen) and hospital information systems, will need to be adapted to comply with EHDS requirements. Germany life sciences regulation will consequently need to accommodate a new layer of data governance that bridges healthcare delivery and pharmaceutical research.

Digital Health Applications (DiGA)

Germany pioneered the regulatory pathway for prescription digital health applications (Digitale Gesundheitsanwendungen, DiGA) through the Digital Healthcare Act (Digitale-Versorgung-Gesetz, DVG) of 2019. The DiGA pathway, managed by BfArM, allows certified digital health apps to be prescribed by physicians and reimbursed by statutory health insurance. As of 2025, the DiGA framework continues to evolve, with increasing attention to interoperability standards, evidence requirements for permanent listing, and the intersection between DiGA and medical device regulation under the MDR and IVDR.

Compliance Strategy: Practical Recommendations for Companies Operating in Germany

Navigating Germany’s life sciences regulatory environment in 2025 demands a multi-layered compliance strategy that addresses EU-level requirements, national implementation measures, and commercial market access considerations simultaneously. The following recommendations reflect the current regulatory landscape:

• Conduct a regulatory horizon scan. Companies should systematically map the EU legislative proposals, including the Pharma Package, EHDS, and EU HTA Regulation, against their product portfolios to identify which changes will affect their marketed and pipeline products.
• Engage early with Notified Bodies. For medical device and IVD manufacturers, securing Notified Body capacity remains critical. Companies should initiate pre-submission discussions well in advance of certification deadlines and consider whether engaging multiple Notified Bodies across different product families could mitigate concentration risk.
• Invest in CTIS competency. Clinical trial sponsors should ensure their regulatory affairs teams are proficient in CTIS operations, including the preparation of compliant dossiers, management of requests for information (RFIs) through the system, and understanding of timelines and procedural triggers.
• Align HTA and market access strategies. With EU joint clinical assessments beginning in 2025, pharmaceutical companies must coordinate their EU HTA engagement (including evidence generation planning) with their existing AMNOG dossier preparation processes.
• Strengthen pharmacovigilance and post-market surveillance systems. Both the proposed Pharma Package and the MDR/IVDR place heightened emphasis on post-authorisation and post-market evidence. Companies should invest in robust signal detection, periodic safety reporting, and post-market clinical follow-up (PMCF) or post-market performance follow-up (PMPF) systems.
• Monitor German legislative developments. National implementing legislation, including amendments to the AMG, MPDG (Medizinproduktedurchführungsgesetz), and associated ordinances, can introduce Germany-specific requirements that go beyond or supplement EU frameworks. Regular monitoring of the Bundesgesetzblatt (Federal Law Gazette) and BfArM announcements is essential.

Looking Ahead: Germany’s Position in the Evolving European Life Sciences Landscape

Germany’s life sciences sector enters the mid-2020s in a position of considerable strength, it is Europe’s largest pharmaceutical market by revenue, a leading clinical trials destination, and home to a robust medical device and diagnostics manufacturing base. However, the regulatory reforms now underway will test the sector’s adaptability.

The likely practical effect of the EU Pharma Package, once finalised, will be to compress the commercial window available to originator companies while simultaneously accelerating market entry for generics and biosimilars. For Germany, where the AMNOG framework already imposes rigorous price negotiations immediately after launch, this could further intensify pricing pressure.

In the diagnostics sector, the IVDR compliance trajectory remains the most immediate operational challenge. Industry observers expect the Notified Body bottleneck to ease gradually as additional bodies are designated and existing bodies expand their capacity, but the transition will continue to demand significant management attention and financial investment through at least 2027.

Germany life sciences regulation is thus characterised by a period of parallel transitions: new pharmaceutical legislation, maturing device and diagnostic regulations, an evolving clinical trial infrastructure, and the emergence of European-level health data governance and HTA. Companies that build regulatory intelligence into their strategic planning, rather than treating compliance as a reactive function, will be best positioned to navigate this complexity and capture the opportunities that Europe’s largest healthcare market continues to offer.

Sources

1. European Commission, Revision of the EU General Pharmaceutical Legislation
2. EUR-Lex, Regulation (EU) 2017/746 (IVDR)
3. EUR-Lex, Regulation (EU) No 536/2014 (Clinical Trials Regulation)
4. European Medicines Agency, Clinical Trials Information System (CTIS)
5. EUR-Lex, Regulation (EU) 2021/2282 (EU HTA Regulation)
6. BfArM, Federal Institute for Drugs and Medical Devices
7. Paul-Ehrlich-Institut (PEI)
8. Gemeinsamer Bundesausschuss (G-BA), Federal Joint Committee
9. EUR-Lex, Regulation (EU) 2023/607 (IVDR Transition Extension)
10. European Commission, European Health Data Space